Advertisement

Topics

In Nonsquamous Lung Cancer, a New Standard of Care (CME/CE)

13:45 EDT 16 Apr 2018 | MedPageToday

(MedPage Today) -- NSCLC patients see big survival boost with pembrolizumab plus chemotherapy

Original Article: In Nonsquamous Lung Cancer, a New Standard of Care (CME/CE)

NEXT ARTICLE

More From BioPortfolio on "In Nonsquamous Lung Cancer, a New Standard of Care (CME/CE)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...